drugset
drugset / Trial / NCT00726726

Drug Interaction Study With a Potential Alzheimer's Disease Compound

NCT00726726 ↗

Phase 1 Completed 22 enrolled Bristol-Myers Squibb
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether BMS-708163 will effect the pharmacokinetics of the commonly prescribed medicines midazolam, warfarin, caffeine,omeprazole and dextromethorphan

Timeline

Start
2008-08
Primary completion
2008-10
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Avagacestat Small molecule 150 mg Oral
Subject Caffeine Small molecule 200 mg Oral
Subject Dextromethorphan Unknown 30 mg Oral
Subject Midazolam Small molecule 5 mg Oral
Subject Omeprazole Other / unclassified 40 mg Oral
Subject Vitamin K Unknown 10 mg Oral
Subject Warfarin Small molecule 10 mg Oral

Indications

Alzheimer disease